Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.51 |
| ▸ | KIF11 | P52732 | 5/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.36 |
| ▸ | PLAU | P00749 | 3/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482538 | 0.88 | CRBN (0.52) | CRBNKIF11NR3C1ARTP53 | |
| SCHEMBL482270 | 0.84 | CRBN (0.48) | CRBNKIF11NR3C1ARTP53 | |
| SCHEMBL482542 | 0.81 | CRBN (0.48) | CRBNKIF11TP53PTGS2PTK2 | |
| SCHEMBL482629 | 0.80 | CRBN (0.51) | CRBNKIF11NR3C1ARBRD4 | |
| SCHEMBL1530506 | 0.79 | CRBN (0.82) | CRBNKIF11NR3C1ARTP53 | |
| SCHEMBL2915245 | 0.78 | CRBN (0.57) | CRBNKIF11NR3C1ARPTGS2 | |
| SCHEMBL896823 | 0.78 | CRBN (0.45) | CRBNTP53PLAUKDM1A | |
| SCHEMBL896311 | 0.77 | CRBN (0.46) | CRBNKIF11NR3C1ARTP53 | |
| SCHEMBL896537 | 0.72 | CRBN (0.59) | CRBNTP53KDM1A | |
| SCHEMBL482659 | 0.72 | CRBN (0.56) | CRBNKIF11NR3C1ARBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637478-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2017-05-02 | — | — | US | disclosed |
| EP-2411352-B1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBVIE INC (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20160368905-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LABORATORIES | 2016-12-22 | — | — | US | disclosed |
| US-9353091-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150056164-A1 | Antiviral Compounds and Uses Thereof | ABBVIE INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-8748443-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120082646-A1 | Antiviral Compounds And Uses Thereof | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150056164-A1 | Antiviral Compounds and Uses Thereof | MAVS, ZC3HAV1, EIF2AK2 | CRBN 2389/4885KIF11 4041/4885NR3C1 3304/4885 |
| US-20160368905-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | MAVS, ZC3HAV1, EIF2AK2 | CRBN 2389/4885KIF11 4041/4885NR3C1 3304/4885 |
| US-20120082646-A1 | Antiviral Compounds And Uses Thereof | MAVS, ZC3HAV1, EIF2AK2 | CRBN 2389/4885KIF11 4041/4885NR3C1 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.